Insider Trading Alert - Alcoa And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 11, 2013, 51 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $33.26 to $7,200,000.00.

Highlighted Stocks Traded by Insiders:

Alcoa (AA) - FREE Research Report

Tata Ratan who is Director at Alcoa bought 2,600 shares at $8.39 on Oct. 11, 2013. Following this transaction, the Director owned 41,379 shares meaning that the stake was reduced by 6.7% with the 2,600 share transaction.

Sorrell Martin who is Director at Alcoa bought 2,480 shares at $8.39 on Oct. 11, 2013. Following this transaction, the Director owned 15,458 shares meaning that the stake was reduced by 19.11% with the 2,480 share transaction.

The shares most recently traded at $7.97, down $0.42, or 5.23% since the insider transaction. Historical insider transactions for Alcoa go as follows:

  • 12-Week # shares bought: 4,940
  • 24-Week # shares bought: 4,940

The average volume for Alcoa has been 19.6 million shares per day over the past 30 days. Alcoa has a market cap of $8.9 billion and is part of the basic materials sector and metals & mining industry. Shares are down 4.38% year to date as of the close of trading on Friday.

Alcoa Inc. engages in the production and management of primary aluminum, fabricated aluminum, and alumina. The company operates in four segments: Alumina, Primary Metals, Global Rolled Products, and Engineered Products and Solutions. The stock currently has a dividend yield of 1.45%. The company has a P/E ratio of 63.8. Currently there are 4 analysts that rate Alcoa a buy, 4 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AA - FREE

TheStreet Quant Ratings rates Alcoa as a hold. Among the primary strengths of the company is its respectable return on equity which we feel is likely to continue. At the same time, however, we also find weaknesses including unimpressive growth in net income, poor profit margins and weak operating cash flow. Get the full Alcoa Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

UDR (UDR) - FREE Research Report

Grove Jon A who is Director at UDR sold 7,000 shares at $23.89 on Oct. 11, 2013. Following this transaction, the Director owned 479,925 shares meaning that the stake was reduced by 1.44% with the 7,000 share transaction.

The shares most recently traded at $23.79, down $0.10, or 0.42% since the insider transaction. Historical insider transactions for UDR go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares sold: 95,400

The average volume for UDR has been 1.7 million shares per day over the past 30 days. UDR has a market cap of $5.9 billion and is part of the financial sector and real estate industry. Shares are down 0.59% year to date as of the close of trading on Friday.

UDR, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It owns, operates, acquires, renovates, develops, redevelops, and manages multifamily apartment communities. The stock currently has a dividend yield of 3.98%. Currently there are 3 analysts that rate UDR a buy, no analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UDR - FREE

TheStreet Quant Ratings rates UDR as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and a generally disappointing performance in the stock itself. Get the full UDR Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Office Depot (ODP) - FREE Research Report

Colligan Thomas J who is Director at Office Depot sold 25,000 shares at $5.03 on Oct. 11, 2013. Following this transaction, the Director owned 63,704 shares meaning that the stake was reduced by 28.18% with the 25,000 share transaction.

Moehler Kim S who is Sr Vice President & Controller at Office Depot sold 9,947 shares at $5.00 on Oct. 11, 2013. Following this transaction, the Sr Vice President & Controller owned 107,745 shares meaning that the stake was reduced by 8.45% with the 9,947 share transaction.

The shares most recently traded at $4.73, down $0.27, or 5.71% since the insider transaction. Historical insider transactions for Office Depot go as follows:

  • 4-Week # shares bought: 9,500
  • 12-Week # shares bought: 14,171
  • 24-Week # shares bought: 16,696
  • 24-Week # shares sold: 25,000

The average volume for Office Depot has been 6.4 million shares per day over the past 30 days. Office Depot has a market cap of $1.3 billion and is part of the services sector and specialty retail industry. Shares are up 41.77% year to date as of the close of trading on Friday.

Office Depot, Inc., together with its subsidiaries, supplies office products and services. Currently there is 1 analyst that rates Office Depot a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ODP - FREE

TheStreet Quant Ratings rates Office Depot as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins and generally high debt management risk. Get the full Office Depot Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Falberg Kathryn E who is EVP and CFO at Jazz Pharmaceuticals sold 3,000 shares at $83.10 on Oct. 11, 2013. Following this transaction, the EVP and CFO owned 134,372 shares meaning that the stake was reduced by 2.18% with the 3,000 share transaction.

The shares most recently traded at $88.97, up $5.87, or 6.6% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 33,208
  • 24-Week # shares sold: 53,208

The average volume for Jazz Pharmaceuticals has been 669,600 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $5.1 billion and is part of the health care sector and drugs industry. Shares are up 65.15% year to date as of the close of trading on Friday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 18.7. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Ascena Retail Group (ASNA) - FREE Research Report

Rayden Michael W who is CEO, Tween Brands, Inc. at Ascena Retail Group sold 20,000 shares at $19.73 on Oct. 11, 2013. Following this transaction, the CEO, Tween Brands, Inc. owned 49,429 shares meaning that the stake was reduced by 28.81% with the 20,000 share transaction.

The shares most recently traded at $20.39, up $0.66, or 3.22% since the insider transaction. Historical insider transactions for Ascena Retail Group go as follows:

  • 4-Week # shares sold: 111,597
  • 12-Week # shares sold: 111,597
  • 24-Week # shares sold: 111,597

The average volume for Ascena Retail Group has been 1.2 million shares per day over the past 30 days. Ascena Retail Group has a market cap of $2.8 billion and is part of the services sector and retail industry. Shares are down 6.23% year to date as of the close of trading on Friday.

Ascena Retail Group, Inc., through its subsidiaries, operates as a specialty retailer of apparel for women, and tween girls and boys. The company operates under the Justice, Lane Bryant, maurices, dressbarn, and Catherines segments. The company has a P/E ratio of 18.2. Currently there are 3 analysts that rate Ascena Retail Group a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASNA - FREE

TheStreet Quant Ratings rates Ascena Retail Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Ascena Retail Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again